Significant Ownership of LIGAND PHARMACEUTICALS INC

Signature - Title
/s/ Octavio Espinoza - Chief Financial Officer
Location
San Diego, CA
Summary
This page shows a list of all the recent SCHEDULE 13D/G filings made by LIGAND PHARMACEUTICALS INC.

Notify me when LIGAND PHARMACEUTICALS INC files a new Schedule 13D/G report.

⭐ Subscribe ⭐

Significant Ownership of LIGAND PHARMACEUTICALS INC

Sym Company Class Ownership Holdings Value Net Change Nb Shares Change % Reporting Name Report Period
PTHS Pelthos Therapeutics Inc. Common Stock, par value $0.0001 per share 50% $145,296,959 +$7,316,652 5,189,177 +5.3% Ligand Pharmaceuticals Incorporated 06 Nov 2025

Schedules 13D/G Reported by LIGAND PHARMACEUTICALS INC:

Sym Target Class Ownership Change Current Shares Change Value Reporting name Form Report Period Filing Date
* An asterisk sign (*) next to the price indicates that the price is likely invalid.